Top section
Top section
Placement 3.7 times subscribed, weeks after regulator halted unauthorised marketing of a purported public offer
Markus Meier and Thore Zimmermann promoted
IPO pipeline strong, but timetables slipping as markets await clarity on tax, growth and defence funding
More articles
More articles
More articles
-
Aligning with a global commercial bank has been on Jefferies’ agenda for several years, but its alliance with SMBC signals an intent to join the investment banking big league. By David Rothnie. -
Idorsia, the Swiss biotech company, has turned to the convertible bond market to finance looming product launches and the development of its late-stage drug pipeline.
-
Mainland-based Jiayi Education Holdings, an after-school tutoring company, has dropped its Hong Kong listing plan following news of a radical change to China’s education sector.
-
Chinese biopharmaceutical company I-Mab is moving ahead with plans for a dual listing in Shanghai, as it looks to broaden its investor base.
-
South Korea’s financial regulator has stepped up scrutiny of big IPOs recently, disrupting a few listings and stoking concerns about a pullback in deal flow. Investors have so far been undeterred — but it’s time they start paying attention.
-
US-style Spac IPOs will soon be possible on the London Stock Exchange following a review by the Financial Conduct Authority, although the changes come at a time when the vehicles have fallen increasingly out of favour with investors.
Sub-sections
shared comment list
